Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company. It is conducting clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Its preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders, such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. The company was incorporated in 2012 and is headquartered in New York, New York. more
Time Frame | SNPX | Sector | S&P500 |
---|---|---|---|
1-Week Return | 6.33% | -0.94% | -2.6% |
1-Month Return | 8.49% | -5.08% | -1.08% |
3-Month Return | -5.47% | -10.62% | 3.45% |
6-Month Return | -34.23% | -6.18% | 8.57% |
1-Year Return | -57.85% | 1.98% | 24.3% |
3-Year Return | -98.67% | -0.93% | 25.58% |
5-Year Return | -96.58% | 33.84% | 84.07% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 4.38K | 4.87K | 4.97K | 5.71K | 6.35K | [{"date":"2019-12-31","value":69.09,"profit":true},{"date":"2020-12-31","value":76.76,"profit":true},{"date":"2021-12-31","value":78.24,"profit":true},{"date":"2022-12-31","value":90.03,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (4.38K) | (4.87K) | (4.97K) | (5.71K) | (6.35K) | [{"date":"2019-12-31","value":-438500,"profit":false},{"date":"2020-12-31","value":-487200,"profit":false},{"date":"2021-12-31","value":-496600,"profit":false},{"date":"2022-12-31","value":-571400,"profit":false},{"date":"2023-12-31","value":-634700,"profit":false}] |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 15.51M | 11.16M | 12.62M | 16.13M | 8.31M | [{"date":"2019-12-31","value":96.15,"profit":true},{"date":"2020-12-31","value":69.14,"profit":true},{"date":"2021-12-31","value":78.2,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":51.53,"profit":true}] |
Operating Income | (15.51M) | (9.46M) | (12.62M) | (26.36M) | (8.31M) | [{"date":"2019-12-31","value":-1551345700,"profit":false},{"date":"2020-12-31","value":-945641000,"profit":false},{"date":"2021-12-31","value":-1261830700,"profit":false},{"date":"2022-12-31","value":-2636099600,"profit":false},{"date":"2023-12-31","value":-831385400,"profit":false}] |
Total Non-Operating Income/Expense | 757.41K | (1.39M) | 14.22K | 10.90M | 3.79M | [{"date":"2019-12-31","value":6.95,"profit":true},{"date":"2020-12-31","value":-12.79,"profit":false},{"date":"2021-12-31","value":0.13,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":34.82,"profit":true}] |
Pre-Tax Income | (15.13M) | (12.70M) | (12.61M) | (5.57M) | (6.04M) | [{"date":"2019-12-31","value":-1513475000,"profit":false},{"date":"2020-12-31","value":-1270319700,"profit":false},{"date":"2021-12-31","value":-1261119700,"profit":false},{"date":"2022-12-31","value":-557395700,"profit":false},{"date":"2023-12-31","value":-603850400,"profit":false}] |
Income Taxes | (378.71K) | 1.55M | (7.11K) | (115.89K) | 7.74M | [{"date":"2019-12-31","value":-4.89,"profit":false},{"date":"2020-12-31","value":19.98,"profit":true},{"date":"2021-12-31","value":-0.09,"profit":false},{"date":"2022-12-31","value":-1.5,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (14.76M) | (14.25M) | (12.60M) | (5.46M) | (13.78M) | [{"date":"2019-12-31","value":-1475604300,"profit":false},{"date":"2020-12-31","value":-1424998400,"profit":false},{"date":"2021-12-31","value":-1260408700,"profit":false},{"date":"2022-12-31","value":-545806700,"profit":false},{"date":"2023-12-31","value":-1377927800,"profit":false}] |
Income From Continuous Operations | (15.13M) | (12.70M) | (12.61M) | (5.57M) | (560.19K) | [{"date":"2019-12-31","value":-1513475000,"profit":false},{"date":"2020-12-31","value":-1270319700,"profit":false},{"date":"2021-12-31","value":-1261119700,"profit":false},{"date":"2022-12-31","value":-557395700,"profit":false},{"date":"2023-12-31","value":-56019000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (14.76M) | (14.25M) | (12.60M) | (5.46M) | (6.04M) | [{"date":"2019-12-31","value":-1475604300,"profit":false},{"date":"2020-12-31","value":-1424998400,"profit":false},{"date":"2021-12-31","value":-1260408700,"profit":false},{"date":"2022-12-31","value":-545806700,"profit":false},{"date":"2023-12-31","value":-603850400,"profit":false}] |
EPS (Diluted) | (8.78) | (13.22) | (2.79) | (2.07) | (1.73) | [{"date":"2019-12-31","value":-877.59,"profit":false},{"date":"2020-12-31","value":-1322.16,"profit":false},{"date":"2021-12-31","value":-279,"profit":false},{"date":"2022-12-31","value":-207,"profit":false},{"date":"2023-12-31","value":-173.19,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
SNPX | |
---|---|
Cash Ratio | 64.74 |
Current Ratio | 65.36 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
SNPX | |
---|---|
ROA (LTM) | -13.82% |
ROE (LTM) | -7.50% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
SNPX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.43 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.57 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
SNPX | |
---|---|
Trailing PE | 0.29 |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.31 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 1.28 |
Synaptogenix Inc (SNPX) share price today is $2.94
Yes, Indians can buy shares of Synaptogenix Inc (SNPX) on Vested. To buy Synaptogenix Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SNPX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Synaptogenix Inc (SNPX) via the Vested app. You can start investing in Synaptogenix Inc (SNPX) with a minimum investment of $1.
You can invest in shares of Synaptogenix Inc (SNPX) via Vested in three simple steps:
The 52-week high price of Synaptogenix Inc (SNPX) is $8.78. The 52-week low price of Synaptogenix Inc (SNPX) is $2.32.
The price-to-earnings (P/E) ratio of Synaptogenix Inc (SNPX) is 0.2921
The price-to-book (P/B) ratio of Synaptogenix Inc (SNPX) is 0.31
The dividend yield of Synaptogenix Inc (SNPX) is 0.00%
The market capitalization of Synaptogenix Inc (SNPX) is $4.07M
The stock symbol (or ticker) of Synaptogenix Inc is SNPX